626 E Whispering Oaks, Palatine, IL 60074
+1-224-678-1803 info@7newswire.com Book A Demo
Newsroom

DUBAI, UAE, March 9, 2024 /7Newswire — Industry-leading fintech firm, SquaredFinancial, launches its Ramadan Special Promotion, empowering investors to unlock their potential during the auspicious season. This exclusive offer gives traders the opportunity to enjoy a 30-day swap-free trading with a maximized leverage of 1:2000 and choose from an array of instruments, ranging from Forex to …

Saturday, March 9 2024, 12:05 PM

DUBAI, UAE, March 9, 2024 /7Newswire — As global mobility and contingency planning become more crucial for investors, the demand for investment migration programs has surged in popularity. According to reports from leading residency and citizenship by investment firm, Savory & Partners, application volumes have been growing exponentially for the past decade. “Every year, we witness …

Saturday, March 9 2024, 12:03 PM

TAMPA, Fla., March 8, 2024 /7Newswire — Lazydays (NasdaqCM: GORV) today reported financial results for the fourth quarter ended December 31, 2023. John North, Chief Executive Officer, commented, “The fourth quarter of 2023 proved to be a challenging operating environment, in particular due to industry wide economic pressures. However, after increasing our marketing budget and aggressively …

Friday, March 8 2024, 7:50 AM

INDIANAPOLIS, March 8, 2024 /7Newswire — Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) expects to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) to discuss the Phase 3 TRAILBLAZER-ALZ 2 trial, which evaluated the efficacy and safety of donanemab in early …

Friday, March 8 2024, 7:41 AM

VANCOUVER, BC, March 8, 2024 /7Newswire – Numinus Wellness Inc. (“Numinus” or the “Company“) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based novel therapies, congratulates Mind Medicine (“MindMed”NASDAQ: MNMD, Cboe Canada: MMED) on the positive data generated from its Phase 2b clinical trial of MM120 (lysergide d-tartrate) …

Friday, March 8 2024, 7:39 AM